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Summary
 
The requirements for interleukin (IL)-12/signal transducer and activator of transcription (Stat)-4
signaling and induction of T cell–specific interferon (IFN)-
 
g
 
 expression in the development of
T helper cell (Th)1–type pathology were examined in two different models of experimental
colitis. In each model, abnormal reconstitution of the T cell compartment in immunodeficient
mice by adoptive cell transfer leads to a wasting syndrome and inflammation of the colon, in-
duced by IFN-
 
g
 
 and tumor necrosis factor (TNF)-
 
a
 
–producing T cells. We show here that
treatment with anti–IL-12 antibodies in one of the models, or reconstitution with T cells from
Stat-4–deficient (Stat-4
 
null
 
) mice in both models resulted in a milder disease in the majority of
recipient animals, compared with those that were left untreated or that had been reconstituted
with 
 
wt
 
 cells. Protected mice in each group also harbored lower frequencies of IFN-
 
g
 
–produc-
ing T cells than did diseased mice, suggesting that effects on wasting and colitis resulted from
the attenuation of IFN-
 
g
 
 expression by T cells. To test whether the development of patho-
genic T cells in the two colitis models was directly dependent on T cell–specific IFN-
 
g
 
 expres-
sion, IFN-
 
g
 
null
 
 donors were used for T cell reconstitution in each system. Surprisingly, large
numbers of IFN-
 
g
 
null
 
–reconstituted mice developed wasting and colitis, which in many cases
was of comparable severity to that seen in animals reconstituted with 
 
wt
 
 cells. Furthermore, T
cells from these animals expressed TNF-
 
a
 
, demonstrating that they had retained the ability to
produce another proinflammatory cytokine. Taken together, these results demonstrate that in
some forms of chronic experimental colitis the development of pathogenic T cells is influenced
predominantly, though not exclusively, by IL-12 via the actions of Stat-4 proteins. Further-
more, our data suggest that in the models of colitis studied here the effects of IL-12/Stat-4 or
other Th1 promoting pathways are not limited to the induction of IFN-
 
g
 
 gene expression in T
lymphocytes.
 
S
 
everal rodent models of chronic intestinal inflammation
share features of immunopathology with human inflam-
matory bowel disease (IBD),
 
1
 
 which exists in the two dis-
tinct forms of Crohn’s disease and ulcerative colitis (1–6).
In particular, the finding that human and many animal
forms of IBD show evidence of aberrant Th1 responses has
come under close scrutiny (5, 7–12). Most recently, it has
been proposed that mucosal inflammation, such as that
found in IBD, emerges from an alteration in the normal
balance between the effects of proinflammatory cytokines
such as IFN-
 
g
 
 and regulatory cytokines such as transform-
ing growth factor 
 
b
 
 (TGF-
 
b
 
; reference 13). The observa-
tion that TGF-
 
b
 
–deficient mice develop inflammation of
various tissues, including the intestine, provides strong evi-
dence in support for this (14). IL-12, a cytokine produced
by activated macrophages and dendritic cells, plays a central
role in the generation of Th1-type responses, characterized
predominantly by the induction of IFN-
 
g
 
 production in T
cells (15–20). In light of this, elucidation of the mechanisms
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by which IL-12 might promote mucosal inflammation is of
clear importance for understanding the pathogenesis of IBD.
Evidence that IL-12 is important in intestinal inflamma-
tion has recently been provided in an experimental model
of acute granulomatous colitis, induced by administration
of trinitrobenzene sulphonic acid (TNBS), which could be
prevented by treatment with an anti–IL-12 antibody (21).
The absence of IFN-
 
g
 
 expression in protected animals in
these experiments was consistent with other data that has
shown that IL-12 activity correlates strongly with IFN-
 
g
 
expression by T cells (19, 22, 23). Recent studies have ex-
tended these observations by demonstrating that induction
of IFN-
 
g
 
 expression in Th1 cells depends largely upon the
activity of intracellular signal transducer and activator of
transcription 4 (Stat-4) proteins, which mediate signals via
the IL-12 receptor (24–28). Although IL-12 activates other
members of the Stat protein family (including Stat-3; refer-
ence 27), the effects of this cytokine on Th1 cell develop-
ment have been shown to depend specifically on expres-
sion of Stat-4. Consistent with this, T cells from Stat-4
 
null
 
mice are almost completely unable to produce IFN-
 
g
 
 in
response to IL-12 and show reduced Th1 responses equiva-
lent to those in IL-12
 
null
 
 mice (28–30).
Although the IL-12/Stat-4 pathway clearly predomi-
nates in the development of Th1 type T cells, Stat-4–defi-
cient T cells are nevertheless capable of limited IFN-
 
g
 
 pro-
duction in response to IL-12–independent stimuli, such as
CD3–IL-2 costimulation (28, 29). Additionally, IFN-
 
g
 
 has
been shown to efficiently augment IL-12–mediated differ-
entiation of Th1 cells (31). These data leave open the possi-
bility that pathways other than that provided by IL-12 and
Stat-4 contribute to the expression of IFN-
 
g
 
 and develop-
ment of Th1-mediated inflammation. Furthermore, such
experiments beg the question as to whether induction of
IFN-
 
g
 
 gene expression in T cells does in fact represent the
critical step in the development and action of pathogenic
Th1 type cells. For example, it is possible that T cells could
be induced into a Th1-like state in the absence of autocrine
IFN-
 
g
 
 expression, and induce pathology through expres-
sion of other proinflammatory mediators. In this study we
sought to examine these questions by testing the extent to
which Stat-4 signaling and the resulting IFN-
 
g
 
 production
by T cells contribute to pathology in two distinct Th1
models of colitis.
In each colitis model, wasting and intestinal pathology
has been shown to be generated by the abnormal recon-
stitution of the T cell compartment in nonallogeneic,
immunodeficient mice. In the first system, we have previ-
ously shown that disease develops after bone marrow cell
(BMC) reconstitution of T cell and NK cell–deficient Tg
 
e
 
26
(C57BL/6 
 
3 
 
CBA/J) mice, using (C57BL/6 
 
3 
 
CBA/J)F1
donor animals (BM
 
®
 
Tg
 
e
 
26) (32–34). In the second sys-
tem, IBD was originally shown to be induced upon recon-
stitution of CB.17 
 
Scid 
 
mice with CD45RB
 
hi
 
 CD4
 
1
 
 T cells
from 
 
wt
 
 Balb/c or CB.17 animals (35–39). In both models,
strong evidence exists to suggest that pathology develops
through a lack of normal T cell regulation. In the case of
the CD45RB
 
hi
 
 transfer model, this occurs due to the ab-
sence of CD45RB
 
lo
 
 CD4
 
1
 
 T cells, which exert their regu-
latory effects through the expression of IL-10 and TGF-
 
b
 
 (38).
Similarly, we have provided evidence in the BM
 
®
 
Tg
 
e
 
26
model that abnormal T cell regulation, resulting from aber-
rant development of thymus-derived T cells, is causal in the
development of pathology in these mice (34). Central to
our hypothesis is the observation that the thymi of Tg
 
e
 
26
mice lack a normal stromal architecture and thus are unable
to support normal ontogeny of 
 
wt
 
 donor–derived thymocytes
supplied by bone marrow inoculation. Consequently, we
have suggested that this defect in thymocyte development
prevents the establishment of a regulated T cell repertoire
in BM
 
®
 
Tg
 
e
 
26 mice.
In both the BM
 
®
 
Tg
 
e
 
26 and CD45RB
 
hi
 
 transfer mod-
els, the notion that T cell dysregulation leads to aberrant
Th1 responses is underscored by the presence of very large
numbers of activated IFN-
 
g
 
– and TNF-
 
a
 
–secreting T cells
in the peripheral lymphoid tissue and the colon (38, 40).
However, despite the similarity of the T cell phenotype in
each model, the resulting pathology in each case is clearly
distinct. Thus, in the BM
 
®
 
Tg
 
e
 
26 mice, inflammation is
limited to the mucosa of the colon and shares some features
of UC, including crypt abscess formation, crypt cell prolif-
eration, and extensive mononuclear cell infiltration. Al-
though these are also characteristic of the CD45RB
 
hi
 
 trans-
fer model, colitis in these mice displays additional features
resembling some of those observed in Crohn’s disease, in-
cluding transmural inflammation, formation of granulomas,
and occasional involvement of the distal small intestine.
These distinctions provide a useful means by which to
compare mechanisms important in alternative forms of
chronic intestinal inflammation. Furthermore, since each
system uses adoptive transfer of cells into T–cell deficient
host animals, both are amenable to a novel experimental
design whereby alternative chimeras can be generated using
donors genetically deficient in specific proteins of interest.
Using this as one of our approaches, we investigated the re-
quirements for IL-12/Stat-4 signaling and induction of T
cell–specific IFN-
 
g
 
 gene expression in the development of
pathology in each form of colitis.
 
Materials and Methods
 
Mice.
 
Donor (C57BL/6 
 
3 
 
CBA/J)F1, C57BL/6, C57BL/6/
 
Scid
 
, and C57BL/6/IFN-
 
g
 
null
 
 mice were purchased from The
Jackson Laboratory (Bar Harbor, ME). The Stat-4
 
null
 
 mice were a
gift from Dr. J.N. Ihle (St. Jude’s Children’s Hospital, Memphis,
TN). 129/SvEv RAG-2
 
null
 
 and 
 
wt
 
 mice were purchased from
Taconic Farms (Germantown, NY). The Tg
 
e
 
26 recipient mice
were generated as previously described by transgenic overexpres-
sion of a full-length human CD3
 
e 
 
gene (32) and bred on the
original C57BL/6 
 
3 
 
CBAJ background in the Beth Israel Dea-
coness Medical Center animal facility. All mice were kept under
standard conditions in microisolator cages with autoclaved food,
water, and bedding. In RAG
 
null
 
 and 
 
Scid
 
 reconstitution experi-
ments, recipients were between 4 and 6 wk of age. Tg
 
e
 
26 recipi-
ent mice were between 5 and 10 wk of age. 
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Cell and Bone Marrow Purification and Cell Transfer.
 
The CD45RB
 
hi
 
model was generated as described by Powrie et al. with minor
modifications (37). CD4
 
1
 
 T cells obtained from the spleens of
donor animals and were enriched by magnetic sorting. For cell
purification, the following biotinylated anti–mouse antibodies
were used to label non-CD4
 
1
 
 T cells isolated from the spleens of
donor mice: B220 (RA3-6B2), Mac-1 (M1/70), Gr-1(RB6-
8C5), and CD8
 
a 
 
(53-6.7). Magnetically labeled streptavidin
beads (Miltenyi Biotec Inc., Sunnyvale, CA) were used to bind
the biotinylated antibodies. All antibodies were obtained from
PharMingen (San Diego, CA). Negative selection was accom-
plished using a MACS magnetic cell sorter (Miltenyi Biotec Inc.).
The enriched CD4
 
1
 
 cells were then labeled for cell sorting with
FITC-conjugated CD45RB (16A) and PE-conjugated CD4
(Becton Dickinson, Mountain View, CA). Subsequently, cells
were sorted under sterile conditions by flow cytometry for CD4
 
1
 
CD45RB
 
hi
 
 cells, using criteria similar to that described in previ-
ous studies (37). This resulted in a 
 
.
 
98% pure population of T
cells. Harvested cells were resuspended at 10
 
6
 
/400 ml PBS (no
FCS) and injected into the tail veins of recipient mice.
For the BM
 
®
 
Tg
 
e
 
26 model, bone marrow was prepared as
previously described (34). In brief, BMCs were depleted of T
cells using two rounds of treatment with anti-Thy1.2 antibody
(30-H12) followed by rabbit complement lysis (Cedarlane Labs,
Westbury, NY). This procedure resulted in ,0.1% CD41 and
CD8a1 cells within the inoculum, as determined by flow cytom-
etry. Bone marrow recipients were total body irradiated with a
sublethal dose (400 rads) 6–8 h before transplant or were treated
with 5-Fluorouracil (75 mg/kg) 48 h before transplantation. 5 3
106–107 cells were resuspended in 400 ml PBS (no FCS) and
transferred by tail vein injection.
To reduce the possibility of graft versus host disease (GVHD)
in the CD45RBhi model, cell transfers were made, where possible,
between mice of the same backgrounds. Stat-4null mice were of the
mixed background C57BL/6 3 129/SvEv, making responses against
segregated minor antigens from the 129/SvEv donor background
a possibility. However, no evidence of GVHD, such as skin in-
flammation, was observed in any of the animals studied. In the
Tge26 bone marrow transfer model, significant differences were
present between donor and recipient mice in some cases. How-
ever, preconditioning of bone marrow was effective in depleting
the BMCs of T cells (see above). Inflammation of the skin and
small bowel were not apparent in the mice included in this study.
Antibody Treatment. The anti–IL-12 antibody (clone C 17.8;
reference 16) was a gift from Dr. T. Veldman (Genetics Institute,
Cambridge, MA). 260 mg of purified anti–IL-12 antibody (or ve-
hicle control [PBS]) was injected intraperitoneally into mice on a
weekly basis starting at the time of BMC transfer.
Disease Monitoring and Scoring. Mice were weighed twice a
week and monitored for appearance and signs of loose stool and
diarrhea. In the BM®Tge26 model, the level of wasting was de-
termined by percentage of loss of weight from the starting
weight, measured at the time of transplant. Weights were subse-
quently ranked 1 point for every 10% of body weight (or part
thereof) lost: 0 5 no weight loss; 1 5 1–10% weight loss; 2 5
11–20% weight loss; and 3 5 >21% weight loss. At necropsy an-
imals were assessed for the level of colitis, which they displayed
using two parameters: colon thickening and stool consistency,
which were subsequently ranked as follows: for colon enlarge-
ment, 0 5 no colon thickening; 1 5 mild thickening; 2 5 mod-
erate thickening; 3 5 extensive thickening; and for stool consis-
tency, 0 5 normal beaded stool; 1 5 soft stool; 2 5 diarrhea; and
an additional point was added if gross blood was noted. The total
score given for disease was the combined scores for colon thick-
ening, stool consistency, and weight loss, divided by three.
Histological Analysis. Colon tissue samples were fixed in 10%
buffered formalin and embedded in paraffin. Sections (4 mm)
were cut and placed on gelatin-coated microscope slides for stain-
ing with hematoxylin and eosin using standard techniques as pre-
viously described (34). The severity of colitis was determined
based on histological examination of the distal colon, whereby
the extent of colonic inflammation was graded on a scale of 0–3
in each of three criteria: cell infiltration, thickening of the bowel
wall, and the number of crypt abscesses. Histological grades were
assigned in a blinded fashion by the same pathologist (A.K. Bhan).
Cell Preparations and Cytokine Analysis. Mesenteric lymphocytes
were harvested and single cell suspensions prepared in PBS with
2% FCS (Intergen, Purchase, NY). Viable cells were counted and
determined by trypan blue exclusion. Surface and cytoplasmic
staining and FACSÒ (Becton Dickinson, Indianapolis, IN) analysis
were performed as previously described (40). All antibodies were
purchased from PharMingen and were conjugated to PE, FITC,
or biotin. In the case of biotin-conjugated antibodies, labeling
was accomplished by secondary staining with streptavidin-RED670
(GIBCO BRL). Cytoplasmic staining for IFN-g (clone XMG1.2)
and TNF-a (clone MP6-XT22) was done as previously described
(40). In brief, freshly isolated cells were stimulated overnight with
plate-bound anti-CD3 (clone 145-2C11). Brefeldin A was added
for the final 2 h of incubation at a final concentration of 10 mg/
ml. Cells were stained with anti-CD4 (clone RM4-5) and anti–
CD3-biotin (145-2C11), washed, and fixed with 2% paraformal-
dehyde (Sigma Chemical Co., St. Louis, MO). Cells were per-
meabilized with Saponin (0.2% in PBS) to facilitate cytoplasmic
cytokine staining. Cells were analyzed by flow cytometry using a
FACscanÒ flow cytometer in conjunction with FACScanÒ software
(Becton Dickinson) and CellQuest Software (Becton Dickinson).
Results
The IL-12/Stat-4 Pathway Predominates in Development of
Wasting and Intestinal Pathology in Two Models of Colitis.
To examine the role of IL-12 in the BM®Tge26 colitis
model, Tge26 mice were transplanted with BMCs from
(C57BL/6 3 CBA)F1 donors as previously described (34)
and given a weekly dose of anti–IL-12 antibody, or vehicle
control (PBS). The requirement for Stat-4 expression in T
cells was tested by comparing disease in Tge26 mice trans-
planted with BMCs from Stat-4null mice or wt control ani-
mals of the same genetic background (129/SvEv). Using a
similar approach in the CD45RBhi model, we used 129/
SvEv RAGnull mice, rather than CB.17/SCID mice, as re-
cipients, allowing us to maintain an equivalent genetic
background to the Stat-4null donor animals (see Materials
and Methods). RAGnull mice were thus reconstituted with
FACSÒ-sorted splenic CD41 CD45RBhi T cells from Stat-
4null mice (Stat-4null®RAGnull). Control RAGnull mice in
these experiments were transplanted with wt 129/SvEv
CD41 CD45RBhi T cells (129/wt®RAGnull).
Treatment of BM®Tge26 mice with anti–IL-12 anti-
body resulted in a significant reduction in disease compared
with control (untreated) mice. A gross clinical disease activ-1228 Role of Stat-4 and IFN-g in Wasting and Colitis
ity score, which measures stool consistency, gross colon en-
largement, and weight loss, is shown in Fig. 1. The differ-
ence in the extent of disease was most apparent between 4
and 5 wk after BMC transfer, where control animals
showed signs of severe cachexia, and in many cases diarrhea
which was occasionally accompanied by visible blood. By
comparison, anti–IL-12–treated animals showed reduced
wasting and generally did not develop diarrhea. At
necropsy, the colons of treated animals were also visibly less
thickened than those of control mice. Similarly, the major-
ity of Tge26 reconstituted with Stat-4null BMCs showed
milder disease compared with control animals that had re-
ceived wt BMC (Fig. 1). 129/wt®RAGnull mice developed
wasting and colitis 7–10 wk after cell transfer. In contrast,
Statnull®RAGnull retained a healthy appearance over the
same period of time and showed mild colitis at necroscopy,
similar to that seen in RAGnull mice that had received
sorted CD41 CD45RBlo T cells (36, 37).
The reduced severity of disease found in each experi-
mental group of mice was reflected both in the extent of
loss of body mass (Fig. 2 A) and for the most part in the level
of mucosal inflammation in the large bowel, determined by
examination of histological tissue sections (Fig. 2 B). Thus,
the extent of mucosal inflammation in all anti–IL-12–treated
F1®Tge26 mice, and the majority of Stat-4null reconsti-
tuted mice, was lower than in control animals. Neverthe-
less, significant histological colitis could be detected in a
proportion of Stat-4null recipient animals, even in cases
where severe gross colitis (extensive colon thickening and
diarrhea) was not apparent. In Stat-4null®RAGnull experi-
ments, a large majority of animals showed considerably
lower grades of colitis than did control mice. Representa-
tive histological sections from colons of CD45RBhi®RAGnull
and BM®Tge26 mice from different groups are shown in
Fig. 3, illustrating the principal differences between mild
and severe forms of colitis in each model. The limited ex-
tent of mucosal inflammation in most of the Stat-4null-
recipients and in those subjected to anti–IL-12 antibody
treatment was evident from the nominal level of cellular
infiltration, crypt cell hyperplasia, and the paucity of crypt
cell abscesses formation. However, it was noted, in the co-
lons of some Stat-4null®RAGnull mice, that even in the ab-
sence of continuous mucosal inflammation there was a
moderate frequency of focal inflammatory involvement. In
some cases this was accompanied by the appearance of
granulomas, a characteristic feature of the CD45RBhi trans-
fer model (Fig. 3 D). Collectively, the use of anti–IL-12
antibodies and Stat-4null mutant mice as donors revealed a
Figure 1. Disease is reduced in the absence of the IL-12/Stat-4 path-
way. Disease activity scores of Tge26 mice that were transplanted with
(C57BL/6 3 CBA/J)F1 BMCs (F1®Tge26) and received a weekly dose
of anti–IL-12 antibody are compared with PBS-treated F1®Tge26 mice
(untreated). Tge26 and RAGnull mice were reconstituted with Stat-4null
BMCs and CD45RBhi CD41 T cells, respectively, and compared with
animals that received 129/SvEv/wt cells. For comparison, results are also
presented from RAGnull mice that received CD45RBlo CD41 T cells
from wt and Stat-4null donors. Clinical disease activity scores were deter-
mined according to parameters of weight loss, colon thickening, and stool
consistency (described in Materials and Methods). The means of collec-
tive individual scores, obtained from three separate experiments, are plot-
ted 6 SD (BM®Tge26 and CD45RBhi transfer groups, n 5 10–15/
group; CD45RBlo, n 5 3–4/group).
Figure 2. Wasting and colitis
are both affected by the absence
of IL-12/Stat-4 signaling. The
divisible components of disease,
weight loss and histological coli-
tis, are represented. (A) Weight
loss. The body weights of ani-
mals measured at the end of each
experiment was divided by the
starting body weight (on the day
of cell transfer), to calculate the
percentage of starting body weight.
Each point represents data from
an individual animal. (B) The
extent of mucosal inflammation
was examined histologically and
graded (see Materials and Meth-
ods). Represented are the com-
bined scores for cell infiltration
(0–3) and colon thickening (0–3)
on a scale of 1–6. Each point
represents the score assigned to
an individual animal.1229 Simpson et al.
predominant role for IL-12 and Stat-4 proteins in the de-
velopment of both the wasting syndrome and colon in-
flammation in two distinct models of IBD.
IL-12 and Stat-4 Cooperate in the Expression of IFN-g by
Th1 Cells. To examine whether disease correlated di-
rectly with the level of Th1 involvement in the two colitis
models, we examined the development of Th1-type T cells
in each system. Since previous studies have shown a direct
effect of IL-12 and Stat-4 on the production of IFN-g by
T cells, we used cytoplasmic staining of IFN-g and FACSÒ
analysis to determine the frequencies of T cells capable of
IFN-g expression. As shown in Fig. 4, the frequency of
IFN-g–producing CD41 T cells in the mesenteric lymph
nodes (MLNs) in anti–IL-12–treated F1®Tge26 mice and
in Stat-4null®Tge26 and Stat-4null®RAGnull mice was 60–
80% lower than in control animals. Additionally, numbers
of colon lamina propria CD41 T cells capable of IFN-g
production were also markedly reduced in protected ani-
mals (data not shown). Previous reports have suggested that
in the absence of Stat-4 signaling T cells develop a Th2-
like phenotype (29). Examination of IL-4 and IL-10 ex-
pression by MLN T cells in Stat-4null recipients revealed no
detectable expression of either cytokine (data not shown).
IFN-g–deficient T Cells Mediate Disease and Produce TNF-a.
Together, the above data implicate a causal relationship be-
tween the numbers of T cells capable of IFN-g production
and the extent of wasting and colitis. We reasoned that if
induction of IFN-g gene expression did in fact represent a
critical step in the development of pathogenic Th1 cells, then
the ablation of this, specifically in T cells, should be suffi-
cient to prevent disease. To test this, we reconstituted the
T cell compartment of Tge26 and Scid or RAGnull mice us-
ing IFN-g–deficient donors (IFN-gnull mice; reference 41).
In the BM®Tge26 model, animals injected with BMCs
from IFN-gnull donors backcrossed to the C57BL/6 back-
ground were compared with controls injected with C57BL/
6/wt BMCs. In the CD45RBhi transfer model, CD45RBhi
CD41 T cells from IFN-gnull mice were transferred into
C57BL/6/Scid or RAGnull mice. Scid and RAGnull mice trans-
planted with C57BL/6/wt CD41 CD45RBhi T cells served
as controls in these experiments. Fig. 5 shows the cumulative
results from these experiments, which compare the mean
disease activity scores from each group. In both BM®Tge26
and CD45RBhi®Scid RAGnull animals little difference was
apparent between the overall gross disease in each group of
mice (Fig. 5). However, in some cases, weight loss and/or
histological colitis were milder in IFN-gnull–recipient mice
(Fig. 6, A and B). A large number of IFN-gnull®Tge26
mice showed a range of histological scores and, in some
cases, despite showing clinical evidence of significant colitis,
Figure 3. Histology of colitis. Sections taken from the distal region of colon are compared after hematoxylin and eosin staining. Objectives are all 310
and scoring is as described in Materials and Methods and Fig. 2. (A) Normal colon taken from an untransplanted Scid mouse. (B) Severe disease (61) in a
RAGnull mouse transplanted with CD45RBhi T cells from a 129/SvEv/wt donor showing extensive cellular infiltration and crypt destruction. (C) Mild
disease (21) in a RAGnull mouse transplanted with CD45RBhi T cells from a Stat-4null donor. The basic structure of the mucosa is intact, but reveals some
infiltration and crypt distortion. (D) Mild disease (21) and presence of a granuloma in a RAGnull mouse transplanted with CD45RBhi T cells from a Stat-
4null donor. (E) Severe disease (51) in a Tge26 mouse transplanted with wt (129/SvEv) bone marrow. Evident is extensive crypt elongation, and a pro-
nounced cellular infiltration. (F) Mild disease (21) in a BM®Tge26 mouse treated with a weekly dose of anti–IL-12 antibody. This section reveals a low
level of cellular infiltrate, moderate crypt elongation, and reduced thickening of the bowel wall.1230 Role of Stat-4 and IFN-g in Wasting and Colitis
revealed comparatively mild inflammation of the mucosa by
histological examination (Fig. 6 B). In CD45RBhi®Scid/
RAGnull experiments, most animals showed visible signs of
wasting. However, due to their young age at the time of
cell transfer, many of these mice increased in body mass
due to compensatory growth. The extent of colon involve-
ment observed in the large majority of CD45RBhi®Scid/
RAGnull mice was equivalent whether or not animals had
received IFN-gnull or C57BL/6/wt T cells. Representative
histological sections from mice that developed colitis in the
presence of IFN-gnull T cells are shown in Fig. 7. In each
case the salient features of pathology were similar to those
in animals reconstituted with wt T cells.
Finally, we observed that large numbers of T cells from
IFN-g–reconstituted animals expressed a pattern of cell
surface markers consistent with an activation or memory
status, including low CD45RB and L-selectin expression
and elevated CD69 expression (data not shown). To exam-
ine whether, in the absence of IFN-g expression, these T
cells retained other characteristics consistent with a patho-
genic phenotype, their ability to produce TNF-a was
tested. As shown in Fig. 8, equivalent frequencies of CD41
T cells from IFN-gnull and wt recipients in each model ex-
pressed TNF-a. Taken together, these data demonstrate
that without producing IFN-g themselves, T cells in each
of the IBD models were nevertheless capable of mediating
significant levels of wasting and colitis that correlated with
the retained capacity of these cells to produce a proinflam-
matory cytokine.
Discussion
In our study we used a novel experimental approach to
examine the mechanisms leading to development and ac-
tion of pathogenic Th1-type T cells in colitis. The signifi-
cant effect of Stat-4 deficiency in limiting progression of
disease in both the BM®Tge26 and the CD45RBhi trans-
fer systems establishes a principal role for this pathway in
the development of pathogenic Th1-type T cells in colitis.
Furthermore, the similar attenuation of both disease and T
cell–specific IFN-g expression seen in anti–IL-12–treated
Figure 4. The effect of the IL-12/Stat-4 pathway on IFN-g produc-
tion by T cells. T cells from the MLNs from each group of BM®Tge26
and CD45RBhi®RAGnull mice were compared for production of IFN-g.
T cells were stimulated overnight using anti-CD3 antibody and stained
for cytoplasmic expression of IFN-g, and the frequency of cytokine posi-
tive cells was assessed by flow cytometry. (A) Dot plots comparing the
frequency IFN-g production by CD41 MLN T cells from BM®Tge26
mice treated with anti–IL-12 antibody or PBS, Stat-4null®Tge26 and
wt®Tge26 controls, and CD45RBhi®RAGnull mice that had received
Stat-4null and 129/SvEv/wt (129/wt) cells. Plots show staining of cytoplas-
mic IFN-g after analytical gating on CD41 T cells. Gates are drawn after
determination of background staining after preblocking with anti–IFN-g
antibodies and staining with isotype control antibodies of irrelevant speci-
ficity. The percentages of positive cells falling in the designated gates are
shown. Frequencies of T cells from healthy wt mice expressing IFN-g af-
ter identical CD3 stimulation or T cells from each of the represented
groups without CD3 staining fall below 1% (data not shown) (B) The
percentages of IFN-g–positive T cells from the MLNs of different groups
of mice were determined. Shown are the mean values 6 SD calculated
for each group (n 5 5–9/group).
Figure 5. T cells deficient in IFN-g production can cause disease in
each of the colitis models. Tge26 mice and C57BL/6/Scid or RAGnull
mice received CD45RBhi CD41 T cells and BMCs, respectively, from
C57BL/6/IFN-gnull donors, and were monitored for disease. These ani-
mals were compared with mice that received cells from C57BL/6/wt
(B6/wt) donors. Plotted are the mean clinical disease activity scores 6 1
SD for each group of animals (n 5 4–12 mice/group). 1231 Simpson et al.
BM®Tge26 mice and Stat-4null®Tge26 mice underscores
the link between the actions of IL-12 and Stat-4. In the
two colitis models studied here, inhibition of IL-12 and/or
Stat-4 signaling affected two divisible aspects of disease,
colitis and wasting, implicating involvement of Th1 cells in
both components of pathology.
To an extent, our experimental results appear consistent
with those obtained in the more acute TNBS-induced
model of colitis (21). However, we observed that although
disease was for the most part attenuated in the absence of
IL-12/Stat-4 signaling, many animals nevertheless revealed
evidence of pathology. Furthermore, this correlated with
the continued (although strongly reduced) presence of T
cells capable of IFN-g expression. These data differ from
those in the TNBS colitis model, where an almost com-
Figure 6. Wasting and colitis
in the absence of IFN-g expres-
sion in T cells. (A) Change in
body weights and (B) histological
colitis are represented as de-
scribed in Fig. 2 in animals re-
constituted with IFN-gnull T
cells. In the CD45RBhi transfer
model, closed symbols represent
RAGnull, rather than Scid recipi-
ents mice.
Figure 7. Histological colitis in IFN-gnull T cell–reconstituted mice.
Sections taken from distal colon are shown from (A) an IFN-gnull®Tge26
mouse with mild colitis (21 histological score), (B) IFN-gnull®Tge26
mouse severe colitis (41 histological score), and (C) IFN-gnull®Scid mouse
with severe colitis (51 histological score).
Figure 8. T cells from IFN-gnull–recipient mice produce TNF-a.
MLN T cells were examined for expression of IFN-g (hatched bars) and
TNF-a (closed bars) using flow cytometry after overnight in vitro stimula-
tion with an anti-CD3 antibody. The mean percentages of cytokine-pos-
itive cells in each group are shown 6 SD (n 5 5–10/group).1232 Role of Stat-4 and IFN-g in Wasting and Colitis
plete inhibition of both disease and IFN-g production
were observed after anti–IL-12 treatment. These differ-
ences make apparent that the mechanisms of pathology in
colitis models studied here and that induced by TNBS are
not equivalent, and they suggest that factors other than IL-
12 contribute to the development of more chronic forms
of intestinal inflammation. In this capacity, the recently de-
scribed IFN-g–inducing factor (IL-18) is a potential candi-
date, since this cytokine has been shown to have a signifi-
cant effect on the long-term ability of T cells to produce
IFN-g (42–44). By inference it is likely that this could signifi-
cantly affect the development of pathogenic Th1-like T cells.
Notwithstanding the above arguments, the results from
our study suggest a degree of independence between the
actions of IL-12 and/or other Th1-promoting cytokines
and the specific expression of IFN-g by T cells. Thus, al-
though the absence of IFN-g expression by T cells altered
the severity of colitis in many cases, the overall effects on
disease were less pronounced than might have been antici-
pated. On first assessment this is surprising, principally for
three reasons. First, the dependence of IFN-g expression
on IL-12 signaling suggests that the effects of IL-12 (via
Stat-4) result from its ability to induce IFN-g transcription
in T cells (22). Second, IFN-g has been shown to be re-
quired for efficient IL-12 priming of Th1 cells, presumably
through autocrine expression (45–47). Principally, this ap-
pears to be achieved through the upregulation of the IL-12
receptor (48–49). Third, a general consensus exists that the
well-documented proinflammatory effects of IFN-g are
central to pathology in IBD (4, 7, 13). The validity of this
last assumption in experimental colitis has been strength-
ened by a previous study by Powrie et al., who demon-
strated that anti–IFN-g treatment was effective in reducing
disease in the CD41 CD45RBhi transfer model (38). It is
possible that in this latter case anti–IFN-g antibody treat-
ment might block all available IFN-g. By contrast, in our
experiments non-T cells, resident in the host animals,
might remain a sufficient source of IFN-g to promote ef-
fects on both T cells and macrophages. However, the de-
velopment of colitis in the absence of IFN-g expression is
not unprecedented, since IL-2null mice, which succumb to
a Th1-type colitis similar to that seen in BM®Tge26 mice,
also develop disease after import of the IFN-gnull mutation
(Zand, M., C. Stevens, and T. Strom, personal communi-
cation). In addition, a recent study by Berg et al. revealed
that antibody neutralization of IFN-g in IL-10null mice was
sufficient to prevent disease only when administered to an-
imals at 3 wk of age and not in animals aged 3 mo or older
(50). Thus, although IFN-g was required to establish colitis
in IL-10null mice, other inflammatory mediators were clearly
sufficient to mediate disease once a pathogenic T cell phe-
notype had been established.
In two autoimmune models classically associated with
Th1-type T cell responses, it has been observed that Th2
cells are also capable of mediating disease (51, 52). These
studies support the contention that, in some cases, immu-
nopathology normally associated with Th1-type responses
can also be attributable to cells that have undergone im-
mune deviation, leading to the expression of Th2-associ-
ated cytokines. However, in our studies we were unable to
detect any IL-4 or IL-10 expression in the absence of either
Stat-4null or IFN-g expression by T cells. Although these
findings do not unequivocally demonstrate lack of immune
deviation, they do argue that this is not predominant in the
colitis models studied here.
Collectively, the results offered here lend credence to
the argument that Th1-type cells develop pathogenicity via
a complex range of mechanisms, not all of which fall under
the influence of IL-12 or their ability to produce IFN-g.
Ultimately, this is most likely achieved by the concerted
expression of a range of cytokines and cytotoxic molecules
which could act directly or indirectly to promote inflam-
mation. TNF-a, which is produced by T cells as well as
macrophages, is a cytokine that encompasses these charac-
teristics and is known to induce potent inflammatory ef-
fects. Consistent with this, we have shown that in colitic
mice T cells expressed TNF-a at a similar frequency
whether IFN-g was expressed by the same cells or not.
Furthermore, we have found that anti–TNF-a antibody
treatment is highly effective in reducing disease in the
BM®Tge26 model.2 Similarly, Powrie et al. demonstrated
an effect of anti–TNF-a treatment in the CD45RBhi ®
Scid model (38). These data are consolidated by the finding
that anti–TNF-a antibody therapy has been shown to be
efficacious in treating Crohn’s disease (53).
In summary, our study offers insights into the require-
ments for both the development and pathogenic activity of
Th1-type cells in two distinct models of inflammatory coli-
tis. The observations that IL-12 is upregulated in human
IBD (7) and that interruption of the TNF-a pathway in-
hibits Crohn’s disease correlate well with our observations
in the two models studied here (38).2 Further dissection of
the pathways which lead to aberrant Th1 pathology in ani-
mal models of IBD will undoubtedly provide a useful
source of information for future therapy in IBD.
2Mackay, F., J. Browning, P. Lawton, S. Shah, M. Comiskey, A.K. Bhan,
E. Mizoguchi, C. Terhorst, and S. Simpson, manuscript submitted for
publication.
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